AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, announced the closing of an oversubscribed $155 million Series B financing.

The financing was led by Venrock Healthcare Capital Partners, co-led by Forbion Growth, and included participation from RTW Investments, Nextech Invest, ARCH Venture Partners, Forbion Ventures, ND Capital, and other new and existing investors. AIRNA will use the proceeds to advance its lead RNA editing product candidate (AIR-001) for AATD into a Phase 1/2 clinical trial, and to develop a pipeline of novel RNA-editing medicines for cardiometabolic and other diseases.